Showing results (121-130 of 150) with videos related to
Sort By:
Pageof 15
The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society|February 1, 1989
MRI of soft tissue vascular malformationsJ A Kalmar, A P Salmon, J J Eick, et al.Radiology|July 11, 2000
Breast cancer in vivo: contrast enhancement with thermoacoustic CT at 434 MHz-feasibility studyR A Kruger, K D Miller, H E Reynolds, et al.The Journal of Clinical Endocrinology and Metabolism|June 18, 1999
Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophyJ A Yanovski, K D Miller, T Kino, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Impact of axillary lymph node dissection on the therapy of breast cancer patientsP P Lin, D C Allison, J Wainstock, et al.Cancer Research|April 20, 2001
The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factorsC J Sweeney, K D Miller, S E Sissons, et al.Lancet (London, England)|March 28, 1987
Hypoglycaemia in African children with severe malariaN J White, K D Miller, K Marsh, et al.The New England Journal of Medicine|December 8, 1988
Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendationsN J White, K D Miller, F C Churchill, et al.The New England Journal of Medicine|September 22, 1988
Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind studyT B Nutman, K D Miller, M Mulligan, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancerK D Miller, W Gradishar, L Schuchter, et al.AIDS (London, England)|September 21, 2000
Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapyH Hatano, K D Miller, C P Yoder, et al.Pageof 15